Improving access to vaccines through tiered pricing

The Lancet

Volumn 383, Issue 9936, 2014, Pages 2265-2267

  Berkley, Seth ^a  

^a The Vaccine Alliance   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; WART VIRUS VACCINE; VACCINE;

CHILD; CHILDHOOD MORTALITY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG INDUSTRY; HEALTH CARE ACCESS; HUMAN; INCOME; INVESTMENT; LOWEST INCOME GROUP; MIDDLE INCOME COUNTRY; NOTE; PNEUMONIA; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; SCALE UP; SOCIAL STATUS; VACCINATION; WORLD HEALTH ORGANIZATION; DEVELOPING COUNTRY; HEALTH; IMMUNIZATION; PROSPECTIVE PRICING; REVIEW;

COSTS AND COST ANALYSIS; DEVELOPING COUNTRIES; DRUG COSTS; DRUG INDUSTRY; HEALTH SERVICES ACCESSIBILITY; HUMANS; VACCINES;

EID: 84903304241     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62424-1     Document Type: Note

References (11)

1. GAVI Alliance. Global level indicators. October, 2013. http://www.gavialliance.org/results/gavi-alliance-goal-level-indicators/ (accessed Jan 7, 2014).
2. Lee LA, Franze l F, Atwell J, et al. The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance. Vaccine 2013; 31S: B61-72.
3. GAVI Alliance. Co untry eligibility policy. 2013. http://www. gavialliance.org/about/governance/programme-policies/countryeligibility/ (accessed Jan 7, 2014).
4. GAVI Alliance. GAVI Alliance graduation policy. Nov 18, 2009. http://www.gavialliance.org/library/gavi-documents/policies/gavi-alliance- graduation-policy/(accessed Jan 7, 2014).
5. Plahte, J. Tiered pricing of vaccines: a win-win-win situation, not a subsidy. Lancet Infect Dis 2005; 5: 58-63.
6. The World Bank. How we classify countries. http://data.worldbank. org/about/country-classifications (accessed Jan 7, 2014).
7. Glassman A, Duran D, Sumner A. Global Health and the new bottom billion: how funders should respond to shifts in global poverty and disease burden. Washington, DC: Center for Global Development, 2012. http://www.cgdev.org/doc/ full-text/BottomBillion/Glassman-Bottom-Billion.html#-ftn2 (accessed July 29, 2013).
8. Yadav P. Differential pricing for pharmaceuticals: review of current knowledge, new findings and ideas for action. London: Department for Internat ional Development, 2010. August, 2010. https://www.gov.uk/government/uploads/ system/uploads/attachment-data/file/67672/diff-pcing-pharma.pdf (accessed Jan 7, 2014).
9. Lopert R, Lang DL, Hill SR, H enry DA. Differential pricing of drugs: a role for cost-effectiveness analysis? Lancet 2002; 359: 2105-07.
10. Cutts F, Franceschi S, Goldie S, et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ 2007; 85: 719-26.
11. Danzon P, Towse A. Differential pricing for pharmaceuticals: reconciling access, RandD and patents. Brookings working paper 03-7. July, 2003. ht tp://regulation2point0.org/wp-content/uploads/downloads/2010/04/phpng.pdf (accessed July 19, 2013).